ArticleBMC endocrine disorders2026
Association between triglyceride-glucose index and diabetic kidney disease in adults with type 1 diabetes.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic kidney disease (DKD) is a major microvascular complication of type 1 diabetes mellitus (T1DM) and is associated with insulin resistance (IR). The triglyceride glucose (TyG) index has been identified as an alternative marker of IR. This study aimed to investigate the association between the TyG index and DKD in in adult patients with T1DM.
methodsA retrospective analysis was conducted on 210 adult patients with T1DM who were admitted to a single center between January 2021 and August 2025. The patients were divided into a non-DKD group (n = 150) and a DKD group (n = 60). They were further categorized into three groups according to tertiles of the TyG index. Demographic characteristics and biochemical parameters were collected and analyzed. Correlation analysis, logistic regression analysis, and receiver operating characteristic (ROC) curve analysis were performed. The calibration curve and decision curve analysis (DCA) were used to evaluate the accuracy and clinical utility.
resultsPatients with DKD had significantly higher TyG values than those without DKD and were more likely to present with chronic diabetic complications and comorbidities (P < 0.05). After adjusting for confounding factors, the TyG index was positively correlated with the urinary albumin-to-creatinine ratio (UACR, r = 0.202, P < 0.05) and negatively correlated with the estimated glomerular filtration rate (eGFR, r = − 0.190, P < 0.05). Logistic regression analysis showed that in Model 3, compared with the T1 group, the odds ratio (OR) for DKD in the T3 group was 2.248 (95% CI: 1.390–3.635, P = 0.001). ROC curve analysis demonstrated that the area under the curve (AUC) for the TyG index was 0.682 (95% CI: 0.605–0.758, P < 0.001), with a sensitivity of 0.750 and a specificity of 0.681. In comparison, the AUCs for the estimated glucose disposal rate (eGDR) and HbA1c was 0.554 (95% CI: 0.467–0.641, P = 0.235) and 0.586 (95% CI: 0.500–0.672, P = 0.059), respectively. DCA confirmed the clinical practicality of TyG model.
conclusionThe TyG index demonstrated a positive association with DKD in patients with T1DM and may serve as an adjunctive marker for early risk stratification or as a component of a multi-marker panel, rather than as a standalone diagnostic tool for DKD. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.